Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles

Journal of Clinical Pharmacology

Volumn 45, Issue 7, 2005, Pages 836-844

  Astruc, Beatrice ^a   Marbach, Peter ^b,d   Bouterfa, Hakim ^b   Denot, Caroline ^a   Safari, Mitra ^b   Vitaliti, Alessandra ^b   Sheppard, Michael ^c  

^a Biotrial ^*  (France)

^b Novartis Pharma AG   (Switzerland)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Long acting octreotide; Modeling; Pharmacokinetics; Prolonged release lanreotide; Safety tolerability

Indexed keywords

ANGIOPEPTIN; LONG ACTING DRUG; OCTREOTIDE; SOMATULINE AUTOGEL;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLELITHIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; HEADACHE; HUMAN; MALE; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; DIARRHEA; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 21044441388     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005277936     Document Type: Article

References (42)

1. Reichlin S. Somatostatin. N Engl J Med. 1983;309:1495-1501.
2. Reichlin S. Somatostatin (second of two parts). N Engl J Med. 1983;309:1556-1563.
3. Bruns C, Weckbecker G, Raulf F, et al. Molecular pharmacology of somatostatin-receptor subtypes. Ann N Y Acad Sci. 1994;733:138-146.
4. Hoyer D, Luhhert H, Bruns C. Molecular pharmacology of somatostatin receptors. Naunyn Schmiedebergs Arch Pharmacol. 1994;350:441-453.
5. Nicholls J, Wynick D, Domin J, Sandler LM, Bloom SR. Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly. Clin Endocrinol (Oxf). 1990;32:545-550.
6. Kutz K, Nuesch E, Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol Suppl. 1986;119:65-72.
7. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide: therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet. 1993;25:375-391.
8. Lancranjan I, Atkinson AB. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary. 1999;1:105-114.
9. Ruhin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600-606.
10. Medical Economics Staff, ed. Sandostatin. In: Physicians' Desk Reference. 55th ed. Montvale, NJ: Thomson Healthcare; 2001.
11. Flogstad AK, Halse J, Bakke S, et al. Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab. 1997;82:23-28.
12. Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf). 1998;48:311-316.
13. Chen T, Miller TF, Prasad P, et al. Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. J Clin Pharmacol. 2000;40:475-481.
14. Zhou H, Chen TL, Marino M, et al. Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects. Br J Clin Pharmacol. 2000;50:543-552.
15. Caron P. Somatuline® Autogel®, a new formulation of lanreotide for the treatment of acromegalic patients [in French]. Ann Endocrinol (Paris). 2002;63:2S19-2S24.
16. Antonijoan RM, Barbanoj MJ, Cordero JA, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol. 2004;56:471-476.
17. Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol. 2004;150:473-480.
18. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146:707-716.
19. Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf). 2000;53:577-586.
20. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2002;87:99-104.
21. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2002;87:3013-3018.
22. Christensen SE, Weeke J, Orskov H, et al. Long-term efficacy and tolerability of octreotide treatment in acromegaly. Metabolism. 1992;41:44-50.
23. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med. 1991; 151:1573-1578.
24. Lamberts SW, van der LeIy AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334:246-254.
25. Kuhn JM, Basin C, Mollard M, et al. Pharmacokinetic study and effects on growth hormone secretion in healthy volunteers of the new somatostatin analogue BIM 23014. Eur J Clin Pharmacol. 1993; 45:73-77.
26. Sassolas G, Khalfallah Y, Chayvialle JA, et al. Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men. J Clin Endocrinol Metab. 1989;68:239-246.
27. Cendros JM, Peraire C, Troconiz I, Obach R. Lanreotide Autogel in acromegaly: a pharmacokinetic and pharmacodynamic analysis. Endocrine Abstracts. 2003;6:P47.
28. Grass P, Marbach P, Brunss C, Lancranjan I, Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism. 1996;45:27-30.
29. Van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol. 2004;150:489-495.
30. Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol. 1999;141:267-271.
31. Turner HE, Vadivale A, Keenan J, Wass JA. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf). 1999;51:275-280.
32. Marbach P, Neufeld M, Pless J. Clinical applications of somatostatin analogs. Adv Exp Med Biol. 1985;188:339-353.
33. Somatuline Autogel [product characteristics]. Berkshire, UK: Ipsen Ltd.
34. Sahin M, Kartal A, Belviranli M, Yol S, Aksoy F, Ak M. Effect of octreotide (Sandostatin 201-995) on bile flow and bile components. Dig Dis Sci. 1999;44:181-185.
35. Shaffer EA. Gallbladder sludge: what is its clinical significance? Curr Gastroenterol Rep. 2001;3:166-173.
36. Sandostatin LAR [product characteristics]. Novartis Pharma AG.
37. Maulding HV. Prolonged delivery of peptides by microcapsules. J Control Release. 1987;6:176.
38. Valery C, Artzner F, Robert B, et al. Self-association process of a peptide in solution: from beta-sheet filaments to large embedded nanotubes. Biophys J. 2004;86:2484-2501.
39. Valery C, Paternostre M, Robert B, et al. Biomimetic organization: Octapeptide self-assembly into nanotubes of viral capsid-like dimension. Proc Natl Acad Sci U S A. 2003;100:10258-10262.
40. Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP, Grossman AB. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol (Oxf). 2000;53:719-724.
41. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24:28-47.
42. Caron P, Bex M, Cullen DR, et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf). 2004;60:734-740.